C200 schreef op 20 september 2018 15:36:
WAINWRIGHT.Pharming Group NV (PHARM.AS)
Rating: Buy
Joseph Pantginis, Ph.D.
646-975-6968
jpantginis@hcwresearch.comFirst Real Knock To Shares an Overreaction; Xanax Not Required; Target Adjusted to
€2.50.CRL received ahead of Friday's PDUFA. This morning, Pharming
announced that it received a Complete Response Letter (CRL) from the
FDA last night regarding Ruconest's sBLA for the prophylaxis setting.
Recall that the PDUFA date was this Friday, September 21. The sBLA
w